CTOs on the Move

Kyverna Therapeutics

www.kyvernatx.com

 
Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases. Our therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of disease. Kyverna is venture-backed and located in the San Francisco East Bay.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Karen Walker
Chief Technology Officer Profile

Funding

Kyverna Therapeutics raised $25M on 01/13/2020

Similar Companies

Neuron23

Neuron23™ Inc. is an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases.

ATAI Life Sciences

Bridging the gap between what the #mentalhealth system can provide and what people need. Interested in #psychedelics, #drugdevelopment, and #AI. CEO @FloBrand.

Dewpoint Therapeutics

Dewpoint Therapeutics is leveraging a transformative shift in the understanding of cellular biology regulation to discover and advance breakthrough small-molecule therapeutics.

AdPharma

AdPharma is a Arlington Heights, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.